Orbimed Advisors LLC Lyell Immunopharma, Inc. Transaction History
Orbimed Advisors LLC
- $4.24 Billion
- Q3 2024
A detailed history of Orbimed Advisors LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 6,086,001 shares of LYEL stock, worth $6.69 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
6,086,001
Previous 6,405,098
4.98%
Holding current value
$6.69 Million
Previous $9.29 Million
9.57%
% of portfolio
0.2%
Previous 0.22%
Shares
3 transactions
Others Institutions Holding LYEL
# of Institutions
122Shares Held
142MCall Options Held
18.1KPut Options Held
200-
Mwg Management Ltd. Washington, DC20.2MShares$22.2 Million30.81% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$16.6 Million13.96% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$16.6 Million42.56% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$11.1 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $273M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...